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It is currently accepted that class I MHC-restricted CTL recognize a processed
form of endogenous antigens . Initial work by Gooding and Townsend and their col-
leagues (1, 2) showed that expression of truncated versions of viral gene products
could render target cells susceptible to CTLlysis . In conjunctionwith other findings,
these data suggested that class I-restricted antigens are likely to be processed by
mechanisms located within the cell cytoplasm (2, 3) . T cell antigens can therefore
be divided into two distinct groups based on separate processing pathways : endoge-
nous, class I-restricted antigens such as viral components, which aredegraded within
the cytoplasm, and exogenous class II-restricted soluble antigens, which are processed
by an endosomal degradation mechanism (2-4) .
We have recently derived class I-restricted CTL specific for the soluble protein
chicken OVA by using atransfected cell line expressing theOVAcDNA (5) . Under
usual circumstances of immunization with soluble OVA, this exogenous antigen is
endocytosedby APC andthen presented exclusively in association with class IIMHC
gene products . Indeed, OVA-specific class I-restricted CTL fail to recognize target
cells in the presence of native OVA, whereas CTL recognition is readily achieved
when OVA is introduced directly into the cell cytoplasm by using osmotic lysis of
pinosomes (5) . This is consistent with a strict requirement for cytosolic antigen lo-
calization for successful class I presentation .
In contast to the resultsobtained with whole proteins, peptide fragments can readily
associate with MHC molecules on target cells surfaces in vitro and are presented
for CTL recognition . This has been demonstrated for a number of viral antigens
(6, 7) and transfected gene products, including OVA (5, 8) . Given the potential for
in vitro CTL recognition of peptide fragments, we set out to determine whether
these same antigenic peptides can prime class I-restricted T cell responses in vivo.
In this report we present evidence to suggest that certain peptides can elicit CTL
after in vivo immunization . However, the ability ofpeptides to direct CTL recogni-
tion in vitro is not sufficient to predict their ability to primeCTL responses in vivo.
In vivo priming appears to require peptide characteristics in addition to the pres-
ence of the CTL targeting determinants .
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Materials and Methods
Mice.
￿
Young adult C57BL/6 mice were obtained from the Scripps Clinic and Research
Foundation vivarium (La Jolla, CA).
mAbs.
￿
The antibodies used in this study were 13.4 (antiThy-1.2 ; reference 9), RL.172 .4
(anti-CD4 ; reference 10), and 3.168 (anti-CD8 ; reference 11) . These were used with guinea
pigC to deplete the appropriate effector cell populations immediatelybefore addition to cy-
totoxicity assays .
Antigens.
￿
OVA (Grade VI ; Sigma Chemical Co ., St. Louis, MO) was used in native and
denatured form or after partial cleavage with trypsin (PT OVA) or overnight cleavage with
cyanogen bromide (CN OVA) . CN OVA was prepared as described previously (5) . Dena-
tured OVAwasthe reduced and alkylated proteinexposed to 8M urea (5) . Separate portions
of denaturedOVA were cleaved with 1% trypsin for 10, 25, and 135 min . Soybean trypsin
inhibitor was added and the three digests were mixed to give the PT OVA preparation . The
synthetic peptides OVA229-276, OVA242-276, and OVA258-276 were synthesized on an automated
peptide synthesizer (Applied Biosystems, Inc., Foster City, CA). All three peptides were made
in a single synthesis starting with the resin-linked carboxyl arginine . Portions ofpeptide resin
were removed after theaddition of residues 258, 242, and 229 to give the respective peptides .
Peptide purity was assessed by HPLC and amino acid analysis .
Target Cells for Cytotoxicity Assays .
￿
Target cells used were the class II negative lines, EL4
(C57BL/6, H-26 thymoma), thymidinekinase-deficient L cells (C3H, H-2'° fibroblast), and
L cells transfected with the H-2Kb gene referred to as L/Kb (12) . EL4 was transfected with
a plasmid containing theOVAcDNA to generate the OVA-producing cell line E.G7-OVA,
and has been described previously (5) .
PrimingMice and Spleen Cell Cultures.
￿
C57BL/6 mice were immunized intravenously with
100,ug OVA, denatured OVA, CNOVA, PT OVAdissolved in PBS, or PBSalone . Mice were
also immunized intravenously with 200 or 20 nmol of synthetic peptides OVA229-276,
OVA242-276, or OVA258-276 dissolved in PBS. 7-15 d later, their spleens were removed and
stimulated in culture . 25-35 x 106 responding spleen cells were stimulated with either 2 x
106 irradiated (20,000 rad) E.G7-OVA cells or 25 x 106 irradiated (3,000 rad) CN OVA-
pulsed syngeneicspleen cells for 5 d in 10 ml ofRPMI 1640 with 10% FCSand 50,uM2-ME
(RP10) in upright 25-cm2 flasks (model 25100 ; Costar, Cambridge, MA) at 37°C in 7%
C02/air. Syngeneic spleen cells were pulsed with CN OVA by suspending 108 cells in 1 ml
ofRP10 containing CN OVA at 500 NAg/ml for 1.5 h at 37°C . CN OVA-pulsed cells were
washed three times with RP10, irradiated, and then used as stimulator cells in culture .
Long-term CTL Lines.
￿
The secondary cytotoxic effector population derived from mice im-
munized with 200 nmol of OVA229-276 was harvested after 7 d of culture . 5 x 106 recovered
cells were restimulated with 2 x 106 irradiated, E.G7-OVA cells and 2.5 x 10' irradiated,
syngeneic spleen cells in 10 ml ofRP10. Subsequent weekly restimulations were carried out
with 2-4 x 106 responder cells, 2 x 106 irradiated E.G7-OVA cells, and 2.5 x 10 7 irradi-
ated, syngeneic spleen cells in 10 ml of RP10 containing 5% supernatant fromCon A-stimu-
lated rat spleen cells and 50 mM a-methyl mannoside in upright 25-cm2 flasks .
CTL Clone. The E.G7-OVA-specific clone 2.4 was derived from E.G7-OVA-primed
C57BL/6 mice and has been described previously (5) . It recognizes OVA258-276 in associa-
tion with H-2Kb .
Cytotoxicity Assays.
￿
Target cells (106) in 600 pl of RP10 were labeled with 300 uCi "Cr
sodium chromate for 45 min . After washing, 10 4 labeled targetsand serial dilutions of effector
cells were incubated in 200 pl of RP10 in round-bottomed 96-well plates . Synthetic peptides
were included in the appropriate assays at 10,ug/ml unless otherwise stated . Aftera4-hincu-
bation at 37°C, 100 j,1 supernatant was collected and specific lysiswas determined as : percent
specific lysis = 100 x [(release by CTL - spontaneousrelease)/(maximum release - spon-
taneous release)] . Spontaneous release in the absence ofCTL was <20% of maximum re-
lease by detergent in all experiments .
Results
In Vioo Priming Using Fragmented OVA.
￿
Class I-restricted CTL derived from
C57BL/6 (H-2n) mice primed with theE.G7-OVA transfectant cell line are specifich
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forthe OVA258-276 determinant restricted to H-2K6 (5). This appears to be the major
or only OVAdeterminant for CTL responses on thetransfected cell line. These CTL
fail to recognize the syngeneictumor target EL4 in thepresence ofnative or denatured
OVA (5). ION OVA sensitizes target cells for OVA-specific in vitro CTL lysis, as do
preparations of OVAthat have been trypsinized forrelatively short periods. Prolonged
trypsinization results in complete proteolysis at lysine 263 situated within the
OVA258-276 determinant with concomitant elimination of all CTL recognition (5).
We began by assessing the ability ofnative OVA, denatured OVA, and CN OVA
to prime for E.G7-OVA-specific CTL in vivo. In addition, we used PT OVA that
consistedof equimolar amounts ofdenaturedOVAdigested with trypsin for 10, 25,
and 135 min. C57BL/6 mice were immunized intravenously with 100 p.g of OVA,
denatured OVA, CN OVA, or PT OVA dissolved in PBS or PBS alone. Spleen cells
were taken 7-15 d later and stimulation in vitro with irradiated E.G7-OVA. Fig.
1 shows that PT OVA was the only preparation to give significant in vivo priming
for a transfectant-specific CTL response. Experiments were repeated using three
separate OVA preparations that had been digested with trypsin for 3.5 min, 7 min,
15 min, or overnight. All threepartial digestsprimed for an E.G7-OVA=specific CTL
response, while the overnighttryptic digest didnot (datanot shown). The specificity
ofthe CTL response wasidenticalto transfectant-primed activity; in both casesCTL
were specific for OVA258-276 restricted to H-2K' (data not shown).
In Vivo Priming Using Synthetic OVA Peptides.
￿
CN OVA, which can sensitize EL4
cellsforlysis by OVAtransfectant-primedor PT OVA-primed CTL, was notcapable
of priming the CTL response when injected into mice in doses up to 1 mg per an-
imal. Fractionation ofCN OVA on Sephadex G50 columns in 50% formic acid and
subsequently on HPLC allowed us to identify two targeting species in the digest:
OVA242-273 and OVA242-285 (5) (methionine 273 is partly resistant to CNBr cleavage
as reported by Nesbit et al. [13]). PT OVA, but not an overnight trypsin digest with
cleavage at 1ys26, served as an efficient in vivo immunogen. We knew that the CNBr
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FIGURE 1.
￿
In vivo CTL primingusingOVA digests. Spleen cells from C57BL/6mice that had
been injected intravenously with 100 kg of OVA (a), denatured OVA(b), CN OVA (c), PT OVA
(d), or with PBS alone(e)were stimulated for5 dwith irradiated E.G7-OVA cells. The resulting
effectors were then tested for lysis of "Cr-labeled (*) E.G7-OVA or (O) EL4 target cells.606
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￿
Amino acid sequence ofOVA peptides. (*) Peptides isolated from CN OVA prepara-
tions (5, 13). (') Synthetic peptides used in this study.
fragments OVA242-273 and OVA242-285 were not priming peptides, yet the PT OVA
peptide probably did not extend beyond 285 because ofthe presence of many tryptic
cleavage sitesjust before this (arg276, lys277, lys279, and arg284) (Fig. 2). The shortest
PT OVA peptide that would contain an intact targeting determinant is OVA229-276 .
This peptide is an extension of the NH2-terminal end of the fragments OVA242-273
and OVA242-285 present in the CN OVA preparations . We reasoned that the differ-
ence in in vivo priming potential observed between CN OVA and PT OVA may
be controlled by the NH2-terminal extension from residue 229 to 242 . To directly
test this hypothesis we synthesized the three OVA peptides with increasing lengths
starting at residue 276 shown in Fig. 2 .
The synthetic peptides offered two main advantages. First, purified synthetic frag-
ments eliminated many of the uncertainties associatedwith the use of poorly defined
peptide mixtures such as PT OVA . Second, all three peptides contained the same
CTL determinant (OVA258-276), since the synthesis was carried out by stepwise elon-
gation of this core sequence. Consequently, all biological differences could then be
unequivocally attributed to the NH2-terminal extensions.
The data in Fig. 3 show that OVA258-276, OVA242-276, and OVA229-276 were approx-
imately equally effective in sensitizing EL4 for lysis by the E .G7-OVA-specific clone
2.4 in a 4-h "Cr-release assay. In contrast to this similarity in in vitro targeting ac-
tivity, OVA229-276 was the only one to give appreciable E.G7-OVA-specific priming
in vivo after intravenous injection (Table 1). In experiment 2 of Table I there was
evidence of weak priming by OVA258-276, but this peptide was still considerably less
FIGURE 3 .
￿
Recognition ofsynthetic OVA peptides by an E.G7-OVA-
specific CTL clone. Lysis of 5'Cr-labeled EL4 by the E.G7-OVA-
specific clone 2.4 was tested in the presence of increasing concentra-
tion of(*) OVA258-276, (/) OVA242-276, or (") OVA229-276 at an E/T
ratio of 10:1 .CARBONE AND BEVAN
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efficient than the longer fragment OVA229-276. We occasionally observed elevated
background lysis using effectors derived from peptide immunized mice, such as the
OVA242-276-immunized animals in experiment 1. However, successful priming was
evident as strong specific lysis of E.G7-OVA compared with EL4 targets. Neither
E.G7-OVA- nor CN OVA-pulsed syngeneic spleen cells gave any primary in vitro
response from spleen cell preparations derived from saline-injected mice. The data
obtained with the synthetic peptides presented in Table I are consistent with the
results obtained using the OVA digests (Fig. 1) and suggest that CN OVA fails to
prime for E.G7-OVA-specific CTL because it lacks the NH2-terminal extension be-
yond residue 242 .
Characterization ofCTL Derivedfrom OVA229-276primedMice.
￿
To further characterize
this response, a CTL line was derived from OVA229-276-primed mice by weekly re-
stimulation with irradiated E.G7-OVA cells in IL-2 containing media. The effectors
were CD8+ T cells, since complement treatment of this line with anti-CD8 or anti-
Thy-1 antibodies abrogated all CTL activity, whereas anti-CD4 had no effect (Fig.
4). The T cells recognized the OVA258-276 determinant, and no activity could be
revealed with the synthetic peptide OVA229-263 (Fig. 5 a) . Finally, CTL reactivity
to OVA258-276 was restricted to H-2Kb , demonstrated by the peptide-specific lysis
of L cell targets transfected with the Kb gene (Fig. 5 b).
TABLE I
CTL Priming after Intravenous Injection of Synthetic OVA Peptides
C57BL/6 mice were immunized with 200 nmol ofeach peptide in Exp. 1 and
20 nmol ofeach peptide in Exp. 2. Controls received PBS alone. Animals were
killed 7 d after immunization.
: Responding spleen cells were stimulated in vitro for 5 d in the presence of ir-
radiated E.G7-OVA cells or irradiated, syngeneic spleen cells that had been
pulsed with 500 pg/ml CN OVA.
5 E/T ratio.
Exp . `
Peptide used
for in vivo
priming
Target
cell
Percent
E.G7-OVA
60:1 §
specific lysis of targets
following secondary in vitro
culture with: :
CN OVA-pulsed
spleen cells
20:1 60:1 20:1
1 OVA242-276 E.G7-OVA 26 14 16 9
EL4 25 16 12 8
OVA229-276 E.G7-OVA 59 39 63 58
EL4 15 8 8 7
None E.G7-OVA 2 0 6 2
EL4 3 1 5 0
2 OVA258-276 E.G7-OVA 21 10 15 9
EL4 11 7 5 6
OVA242-276 E.G7-OVA 8 3 0 0
EL4 3 2 3 3
OVA229-276 E.G7-OVA 53 29 64 52
EL4 10 6 4 5
None E .G7-OVA -1 -2 -4 -3
EL4 2 4 2 1608
￿
INDUCTION OF CYTOTOXIC T CELLS BY PEPTIDE IMMUNIZATION
100,
0J
10:1 3:1 1:1
Effectorl Target Ratio
FIGURE 4.
￿
Peptide-primed, E.G7-OVA-specific effectors are CD8` T
cells. A CTL line derived from OVA229-276-primed mice was treated with
complement in the presence of(*) antiThy-1, (/) anti-CD8, (") anti-
CD4 antibody, or (O) no antibody before addition to "Cr-labeled
E.G7-OVA.
Discussion
We have shown that intravenous injection of C57BL/6 mice with the OVA229-276
peptide in saline elicits CTL that are identical to those derived from EM-OVA-
primed mice in terms of antigen specificity and MHC restriction. These effectors
clearlydiffer from thoseinducedby primary, in vitro stimulation of C57BL/6 spleen
cells with OVA peptides that we have described previously (14). In vitro culture of
naive splenocytes in the continuous presence of CN OVA elicits CTL that are largely
specific for a determinant distinct from OVA258-276 and that show a broad MHC
crossreactivitypattern(14). A minorcomponent within this bulk population is specific
for OVA258-276 in association with H-2Kb (data not shown). All CTL induced
against OVA digests or synthetic OVA peptides by primary in vitro stimulation fail
to lyse E.G7-OVA targets (14), in contrast to those derived by in vivo priming with
OVA229-276 (Table 1) or PT OVA (Fig. 1). Neither CN OVA-pulsed cells (Table I)
norE.G7-OVA (Fig. 1 andTable 1) stimulate OVA-specific primary CTL responses
in vitro. We suspectthat this failurereflects low densitiesof cell surface MHC-peptide
complexes as discussed earlier (14).
E.G7-OVA-specific effectors from OVA229-276-primed mice express CD8, not CD4,
and are specific for the OVA258-276 determinant in association with H-2Kb . Ourdata
too
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FIGURE 5.
￿
MHC-restricted peptide reactivity ofpeptide-primed,
E.G7-OVA-specific CTL. (a) A long-term CTL line derived from
OVA229-276-primed mice was tested for lysis of EL4 in the pres-
ence of 10 ug/ml ( ") OVA2se-276; (*) OVA229-263, or (O) media
alone. (b) The same CTL line w9s tested for lysis of L/I4b cells
(closed symbols) or L cells (open symbols) in the presence ( " ; O) or
absence (/, p) of 10 Wg/ml OVA2s8-276 .CARBONE AND BEVAN
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do not rule out the possibility that peptides longer than OVA229-276 in PT OVA can
also prime a similar CTL response, only that whole OVA is unable to do so. We
have failed to induce any transfectant-specific CTL using native OVA at doses from
100 ug to 1 mg per animal. It should be emphasized that we set out to compare
exogenous peptide immunization with priming by cells that endogenously express
the protein. Consequently, we have concentrated exclusively on E.G7-OVA-specific
T cells, whereas OVA priming may elicit CTL that have other specificities (15). It
has also been reported previously that complete OVA digests fail to prime CTL in
vivo (15). This is consistent with ourcurrent studies. We extend theseearlier findings
by suggesting that the failure in H-2b mice results from deletion of residues in the
N terminal to position 242. Thus, OVA229-276 can prime a CTL response, whereas
OVA242-276 or the CN OVA peptides OVA242-285 and OVA242-273 fail to do so.
It is possible that the OVA segment between residues 229 and 242 represents a
Th determinant that is required for optimal CTL induction. To our knowledge no
such helper determinant has been mapped to this region. Furthermore, this expla-
nation would appear unlikely since native OVA that clearly contains this region is
not an immunogen in this assaysystem. A second possibility to explainthe immunoge-
nicity of OVA229-276 could involve an enhanced peptide-MHC association for the
longer peptides. The dose titrations presented in Fig. 3 would argue against this
since all three peptides have the same potency for CTL targeting in vitro.
Given theirpotentialfor CTLactivation in vitro, it might at firstappear surprising
that OVA242-276 and OVA258-276 fail to elicit CTL in vivo. We have recently demon-
strated that peptides can sensitize glutaraldehyde-fixed target cells for lysis by the
E.G7-OVA-specific clone 2.4 (16). Therefore, in vitropeptide-MHC association can
obviously occur at the cell surface and does not require access to the intracellular
pathwayofclass I antigen presentation. Recent work by Hosaka, Bennink, Yewdell,
and coworkers (17, 18) on the traditional class I-restricted antigen, influenza virus,
demonstrated that access to this intracellular pathway is essential for in vivo CTL
priming. While it is generally accepted that noninfectious virus preparations fail
to immunize CTL, they demonstrated that inactivated influenzavirus can success-
fully vaccinate CTL so long as it introduces sufficient viral components directly into
the cell cytoplasm (17, 18). We have previously shown that native OVA fails to pro-
vide peptides that associate with class I MHC molecules unless it is directly intro-
duced into the target cell cytoplasm for intracellular degradation (5). Our results
presented here show that OVA229-276 is distinct from whole OVA and the shorter
targeting peptides, such as CN OVA or OVA258-276, in its ability to prime CTL in
vivo. We suggest that this priming reflects a capacity forOVA229-276 to enter the class
I presentation pathway in vivo. Antigenic peptides that canonly associate with MHC
at the cell surface may behave like other exogenous molecules and fail to elicit a
class I-restricted response.
To date there have been no other reports of successful in vivo priming of CTL
using synthetic targetingpeptides. We have injected C57BL/6mice with the 16-residue,
D'-restricted influenza nucleoprotein peptide (residues 365-380) originally
identified by Townsend et al. (6) and found no evidence for influenza-specific CTL
priming with doses comparable with the ones used in this study (data not shown).
Most class I-restricted targeting peptides could therefore resemble OVA258-276 rather
than OVA229-276 and fail to prime CTL in vivo.610
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The mechanism by which OVA229-276 may enter the class I presentation pathway
is completely unknown. It is intriguing that this same peptide, but not the native
protein, was shown to inhibit protein translocation across the endoplasmic retic-
ulum in an in vitro translation system (19). The authors concluded that residues
234-254 contained the signal sequence for OVA secretion. While the significance
ofthis observation remains controversial interms of OVA secretion(20, 21), the fact
remains that this peptide exhibits a second unusual biological characteristic that
could be associated with its immunological function that we have uncovered. Per-
haps OVA229-276 is unusual in that it can pass through the cell membrane from the
outside, possibly after endocytosis. Thus, the enhanced immunogenicity observed
as the peptide length is increased from OVA258-276 to OVA229-276 may reflect the con-
formational constraints thought to maintaincorrect peptide-bilayerinteractionduring
membrane translocation (22, 23).
There isgood evidence thattheclassI and class IIMHC-encodedmolecules function
as restriction elements for peptides that derive from separate antigenprocessing and
presentation systems (3, 24, 25). Most exogenous solubleproteins, such as OVA and
inactivated virus particles thatcannot fuse with cells, fail to activate class I-restricted
T cells in vivo or in vitro. The peptide OVA229-276 is an obvious exception to this
rule since it can prime H-2K6-restricted CTL after injection into mice. There are
other examples in the literature of successful in vivo induction ofclass I-restricted
Tcells by peptide (26) or purified viral protein preparations (27-29). Whether these
successes depend on special properties of the polypeptides themselves or on effects
ofthe adjuvants used is not known. It has been suggested that specialized APC can
phagocytose other cells and cycle the degradation products into their class I presen-
tation system (4). Thus, soluble proteins that become associated with cells that are
then phagocytosed could enter the class I pathway by this route. It has also been
reported that virus-specific, class I-restricted T cells can be restimulated in vitro
with purified proteins. For example, influenza hemagglutinin (30, 31) and hepatitis
B surface antigen (32) reactivate memory CTL during in vitro culture. One expla-
nation forthis may be that theproteins are processed (i.e., degraded) extracellularly
to expose the class I-restricted epitopethat binds the MHC molecule on the surface
ofthe stimulator cell. These would then be examples ofcell-free antigen processing
and would not reflect the ability of soluble antigen to enter the class I pathway of
antigen processing and presentation. Indeed, we have reported that serum compo-
nents can process denatured OVA (5).
We have definedthe minimum sequential requirement for direct priming within
the OVA-H-2K' system. Analysis of the conformational characteristics associated
with this priming peptide will provide us with valuable structural data that could
then be applied tootherclassI-restricted systemssuchasinfectious virus preparations.
Summary
CTL recognize peptide forms of processed, foreign antigens in association with
class I moleculesencoded bytheMHC andareusuallydirected againstendogenously
synthesized"cellular antigens," such as those expressed byvirus-infected cells. Invitro
studieshave shown that small exogenous peptides can directly associate with class I
molecules on the cell surface and mimic the target complex derived by intracellular
processing and presentation. We have recently generated OVA-specific, H-2Kb-re-
stricted CTLby immunizing C57BL/6 mice with a syngeneic tumor line transfectedCARBONE AND BEVAN
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with the OVA cDNA. The CTL recognize the OVA transfectant EM-OVA and
the synthetic peptide OVA258-276, but fail to recognize the native protein. We rea-
soned that given the potential for direct peptide/class I association observed in vitro,
OVA258-276 may induce CTL after in vivo priming. However, we found that this is
not the case. OVA258-276 and peptides of increasing lengths up to OVA242-276 and
OVA242-285, which are all able to form the target complex in vitro, are inefficient
at priming E .G7-OVA-specific CTL responses after intravenous injection. This is
also true for both native and denatured OVA . In contrast to these results, the syn-
thetic peptide OVA229-276 corresponding to a peptide in a partial tryptic digestion
ofOVA can efficiently prime C57BL/6 mice in vivo after intravenous injection. This
peptide elicits CTL that appear identical to those derived from animals immunized
with syngeneic cells producing OVA endogenously. These results are discussed in
terms of separate class I and class II antigen presentation pathways and the ability
of only certain, exogenous antigens to enter the cytoplasmic, class I pathway.
We thank Sandra J. Sterry for excellent technical assistance and Holly Brewer for typing
this manuscript.
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